Lv1
20 积分 2022-07-22 加入
Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009–2024)
15小时前
已完结
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
16小时前
已完结
Is HIF activation Janus faced? The therapeutic effects of the HIF-2α inhibitor
7天前
已完结
Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease
16天前
已完结
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
16天前
已完结
Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors
17天前
已完结
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules
20天前
已完结
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules
20天前
已完结
Translational PK–PD for targeted protein degradation
1个月前
已完结
Methods and cell-based strategies to produce antibody libraries: current state
2个月前
已完结
皖公网安备34019202002308
